Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
8.16
Nov 19 • 3:59 PM ET Dollar change-0.02 Percentage change(-0.24%)
Aftermarket Close
8.09
Aftermarket • 7:46 PM ET Dollar change-0.07 Percentage change(-0.86%)
Index
RUT
Market Cap
1.41B
Enterprise Value
1.24B
Income
-125.67M
Sales
1.49M
Book/sh
1.27
Cash/sh
1.01
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
140
IPO
Jul 22, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
946.05
P/B
6.43
P/C
8.11
P/FCF
-
EV/EBITDA
-
EV/Sales
831.66
Quick Ratio
9.64
Current Ratio
9.64
Debt/Eq
0.02
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-0.79
EPS next Y
-0.74
EPS next Q
-0.20
EPS this Y
5.82%
EPS next Y
5.96%
EPS next 5Y
3.59%
EPS past 3/5Y
9.99% -9.45%
Sales past 3/5Y
-21.31% -10.14%
EPS Y/Y TTM
12.12%
Sales Y/Y TTM
-47.18%
EPS Q/Q
2.95%
Sales Q/Q
-19.58%
Insider Own
13.68%
Insider Trans
0.05%
Inst Own
84.55%
Inst Trans
18.66%
ROA
-51.87%
ROE
-58.59%
ROIC
-57.17%
Gross Margin
-635.71%
Oper. Margin
-9155.35%
Profit Margin
-8451.31%
SMA20
-15.84%
SMA50
-14.91%
SMA200
17.79%
Trades
Shs Outstand
172.38M
Shs Float
149.12M
52W High
12.54 -34.95%
52W Low
2.24 264.29%
Volatility
11.06% 10.85%
ATR (14)
1.00
RSI (14)
42.48
Beta
2.26
Rel Volume
1.27
Avg Volume
4.02M
Volume
5,083,507
Perf Week
-10.67%
Perf Month
-18.73%
Perf Quarter
-14.55%
Perf Half Y
60.31%
Perf YTD
133.81%
Perf Year
185.31%
Perf 3Y
462.76%
Perf 5Y
-26.15%
Perf 10Y
-
Prev Close
8.18
Price
8.16
Change %
-0.24%
Consensus
Strong Buy
Avg. Price Target
$15.09
Implied Upside
+84.9%
Analysts16incl. previous ratings
Rating Distribution12 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 29, 2026Initiated
JEF logoJJefferies
Buy$14+71.6%
Jun 04, 2026Initiated
LLeerink Partners
Outperform$12+47.1%
May 28, 2026Initiated
BBTIG Research
Buy$9+10.3%
Jan 08, 2026Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$4.32-47.1%
Oct 02, 2025Initiated
JPM logoJJP Morgan
Overweight
Jul 03, 2025Resumed
MS logoMMorgan Stanley
Overweight$7-14.2%
Jan 22, 2025Initiated
NNeedham
Buy$9+10.3%
Oct 02, 2024Initiated
GGuggenheim
Buy$10+22.5%
Jul 03, 2024Initiated
MS logoMMorgan Stanley
Overweight$7-14.2%
Mar 14, 2024Initiated
BNS logoBScotiabank
Sector Outperform$13+59.3%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szela Mary TDirectorJun 30 '26Buy11.5412,900148,86621,300Jul 06 04:06 PM
Pangalos Menelas NDirectorMay 13 '26Buy5.3637,453200,748232,308May 13 04:05 PM
Busch AndreasChief Innovation OfficerMar 12 '26Buy2.29100,000229,000421,446Mar 16 04:17 PM
Pangalos Menelas NDirectorFeb 27 '26Buy2.7475,095205,760189,055Mar 03 04:13 PM
McClain SeanChief Executive OfficerFeb 23 '26Option Exercise1.21396,399479,6438,730,966Feb 25 06:05 PM
McClain SeanChief Executive OfficerFeb 02 '26Sale2.9926,76180,0158,334,567Feb 04 04:52 PM
Jonasson ZachariahCFO / CBOFeb 02 '26Sale2.9917,49652,313383,538Feb 04 04:51 PM
VAN HOUTEN FRANSDirectorDec 05 '25Buy3.7240,000148,80063,320Dec 09 04:04 PM
Absci Corp. engages in drug discovery with generative design to create biologics for patients. Its platform combines AI models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. The firm has its own pipeline of AI designed therapeutics including ABS-201 and ABS-202. Absci Corp was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
FounderMr. Sean McClain
Chief Business Officer & CFODr. Zachariah Jonasson Ph.D.
Senior VP & Chief Accounting OfficerMr. Todd Bedrick CPA
CVP of Finance & Head of Investor RelationsMr. Alexander Khan CPA
Chief Legal OfficerMs. Shelby Walker J.D.